Category Archives: Other

Jilin Implements National Essential Medicines List 2026 Identification

Changchun, Aug 25, 2026 — Jilin Province’s Public Resources Trading Center ordered drug marketing authorization holders to verify and confirm essential medicines labeling for all platform-listed products by Sept 30, 2026, as the province prepares to synchronize the 2026 National Essential Medicines List with its procurement systems starting Sept 1.

Policy Snapshot

AttributeDetail
IssuerJilin Public Resources Trading Center
DocumentNotice on the Implementation of the National Essential Medicines List (2026 Edition) Identification
PlatformJilin Medical Insurance Information Platform — Drug and Medical Consumables Procurement Management Subsystem
First sync dateSept 1, 2026 (for products confirmed by Aug 31, 2026)
Hard deadlineSept 30, 2026
ScopeAll online-listed drugs; newly listed products on rolling basis

Implementation Roadmap

  • Phase 1 (by Sept 30, 2026): Enterprises log into the procurement subsystem to confirm or request adjustments to essential medicines attributes for currently listed products. Items verified by Aug 31, 2026 sync to the trading catalog on Sept 1, 2026.
  • Phase 2 (by Sept 30, 2026): Correction requests for mislabeled products processed in batches. No further applications accepted after the deadline.
  • Ongoing: For newly listed products, manufacturers submit essential medicines attributes monthly on the 5th–7th (holidays deferred) during qualification maintenance.

Market Impact Analysis

The Sept 1 synchronization deadline creates a compressed compliance window for pharmaceutical firms operating in Jilin, a northeastern province serving roughly 24 million residents. Companies that fail to verify their National Essential Medicines List status by Sept 30 risk having the trading center assign labels unilaterally, potentially misclassifying products and affecting hospital procurement priority. The two-phase approach—confirmation followed by correction—reflects regulators’ effort to minimize disruption while ensuring the 2026 catalog accurately maps to the province’s online trading system.

For manufacturers, essential medicines designation carries significant commercial weight: listed products receive preferential procurement status in public hospitals and primary care facilities under China’s tiered diagnosis framework. Misclassification could mean exclusion from priority purchasing protocols or, conversely, incorrect inclusion that triggers audit scrutiny. The monthly maintenance window for new listings introduces a predictable rhythm but demands ongoing regulatory vigilance.

Forward-Looking Statement

Industry analysts expect Jilin’s implementation template to be replicated across additional provinces as the 2026 National Essential Medicines List rolls out nationally. The unilateral labeling fallback—where the trading center assigns attributes for non-responsive firms—signals a hardening regulatory stance on compliance automation rather than negotiated accommodation. Pharmaceutical companies with broad national formularies should treat Jilin’s Sept 30 deadline as an early indicator of provincial procurement timelines, with neighboring Heilongjiang and Liaoning likely to issue parallel notices before year-end. The integration of essential medicines attributes directly into procurement transaction catalogs suggests future tenders will increasingly automate prioritization, reducing manual intervention but raising the stakes for data accuracy at the enterprise level.-China Health Reform Pulse

Policy Source: http://www.ggzyzx.jl.gov.cn/jyxx/yxcg/yp/202608/t20260825_3665445.html

Qinghai Adds Flu Vaccines to Non-Immunization Procurement List

Xining, Aug 25, 2026 — Qinghai Province’s Center for Disease Control and Prevention released the second batch of expert demonstration results for its 2026 non-immunization vaccine procurement expansion, clearing three influenza vaccine products for online platform listing after a July 8 expert review session.

Procurement Roster

No.Generic NameDosage FormSpecificationPackagingManufacturerApplicantPrice (CNY)
1Influenza Virus Split VaccineInjection0.5 ml/vialVialHualan Biological Vaccine Inc.Hualan Biological Vaccine Inc.78.00
2Influenza Virus Split VaccineInjection0.25 ml/dosePre-filled SyringeHualan Biological Vaccine Inc.Hualan Biological Vaccine Inc.68.00
3Influenza Virus Subunit VaccineInjection0.5 ml/dosePre-filled SyringeZhongyi Anke Biotechnology Co., Ltd.Zhongyi Anke Biotechnology Co., Ltd.268.00

Regulatory Context

The results follow Qinghai CDC Bureau [2025] No. 39, the provincial implementation plan for centralized online procurement of non-immunization vaccines. The review process encompassed enterprise application, documentation screening, on-site price negotiation, and expert panel certification. All three products were deemed compliant after supplementary materials were submitted. The public comment window runs from Aug 25 to Sept 1, 2026.

Market Impact Analysis

The inclusion of two Hualan Biological split-virus influenza vaccines and one Zhongyi Anke subunit formulation expands Qinghai’s elective flu vaccine portfolio ahead of the autumn immunization season. Hualan’s dual-format offering—vial and pre-filled syringe at 78 yuan and 68 yuan respectively—targets different age groups and procurement budgets, while Zhongyi Anke’s premium subunit vaccine at 268 yuan positions itself as a high-efficacy alternative in a province where vaccine access has historically been constrained by logistics and cold-chain infrastructure.

The 68-yuan to 268-yuan price spread reflects a tiered market strategy, allowing public health facilities to match vaccine selection to patient affordability and clinical indication. For manufacturers, securing slots on Qinghai’s non-immunization procurement platform guarantees formulary access across the province’s public vaccination network, a critical channel in a region with limited private clinic penetration.

Forward-Looking Statement

Industry analysts expect the three products to clear the one-week public comment period without material objections, enabling formal platform listing before the peak flu vaccination window opens in October. The July expert review and August publication timeline suggest Qinghai is front-loading its non-immunization vaccine procurement calendar, potentially signaling earlier-than-usual provincial tendering cycles for 2026. Hualan Biological’s dominant position in this batch—two of three slots—reinforces its standing in China’s seasonal flu vaccine market, while Zhongyi Anke’s subunit entry at a 3.4x price premium tests demand elasticity for advanced influenza formulations in western China.-China Health Reform Pulse

Policy Source: https://www.qhcdc.org.cn/xwzx/tzgg/content_3900

Guangdong Adds Fourth Batch of Non-Immunization Vaccines to 2026 Program

Guangzhou, Aug 24, 2026 — Guangdong Province expanded its 2026 non-immunization vaccine program by releasing the fourth batch of supplementary products and updating the provincial usage catalog, as the region continues to broaden access to elective vaccines outside the national compulsory immunization schedule.

Policy Snapshot

AttributeDetail
IssuersGuangdong Provincial Center for Disease Control and Prevention; Guangdong Drug Exchange Center
DocumentNotice on the Announcement of Supplementary Products (Fourth Batch) and Updated List of Non-Immunization Vaccines in the 2026 Guangdong Province Vaccination Program
Legal basisGuangdong CDC Bureau [2025] No. 3 (Implementation Plan for Centralized Procurement of Non-Immunization Vaccines in Guangdong Province)
ActionRelease of fourth supplementary batch; synchronized update of 2026 non-immunization vaccine usage catalog
Effective catalog dateUpdated to Aug 24, 2026

Catalog Updates

The announcement adds a fourth tranche of products to the province’s 2026 non-immunization vaccine directory, which covers elective vaccines outside China’s compulsory national immunization program. The updated catalog, current as of Aug 24, 2026, consolidates all approved non-immunization vaccines available for centralized procurement across Guangdong’s vaccination network.

Market Impact Analysis

The fourth supplementary release signals sustained demand growth for elective vaccines in Guangdong, China’s most populous province with roughly 127 million residents. By maintaining a rolling update mechanism for the non-immunization vaccine catalog, regulators are creating multiple entry windows for manufacturers each year, reducing the barrier for new products to access the provincial market.

For vaccine developers and distributors, inclusion in the updated directory is a prerequisite for participation in Guangdong’s centralized procurement system, which governs public hospital and community health center purchases. The release timing—late August—allows suppliers to position products ahead of the autumn vaccination season, typically a peak period for influenza, pneumococcal, and other elective immunizations.

Forward-Looking Statement

Industry analysts expect Guangdong’s rolling catalog update model to be adopted by additional provinces as China decentralizes non-immunization vaccine procurement authority. The fourth batch release suggests the 2026 program is approaching full coverage scope, though further supplementary announcements before year-end remain possible if new products complete regulatory approval. Manufacturers with pipeline candidates for human papillomavirus, shingles, or combination pediatric vaccines should monitor the Guangdong template closely, as the province’s catalog decisions often influence neighboring jurisdictions in the Pearl River Delta region.-China Health Reform Pulse

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=2091877607866896384